[go: up one dir, main page]

MX2016001465A - Composiciones topicas para el tratamiento de sudoracion excesiva y metodos para utilizar las mismas. - Google Patents

Composiciones topicas para el tratamiento de sudoracion excesiva y metodos para utilizar las mismas.

Info

Publication number
MX2016001465A
MX2016001465A MX2016001465A MX2016001465A MX2016001465A MX 2016001465 A MX2016001465 A MX 2016001465A MX 2016001465 A MX2016001465 A MX 2016001465A MX 2016001465 A MX2016001465 A MX 2016001465A MX 2016001465 A MX2016001465 A MX 2016001465A
Authority
MX
Mexico
Prior art keywords
treatment
methods
excessive sweating
topical compositions
sweating
Prior art date
Application number
MX2016001465A
Other languages
English (en)
Inventor
Teodora X Pune-Dumitrescu
Elizabeth K Hussey
Jon Lenn
Leandro L Santos
Virginia D Schmith
Maria Graziella Larm
Leon Loupenok
Michael R Luke
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51626097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016001465(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MX2016001465A publication Critical patent/MX2016001465A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención contempla 4-[hidroxi(difenil)metil]-1-{2-[(f enilmetil)oxi]etil}-1-azoniabiciclo[2.2.2]octano y un anión farmacéuticamente aceptable del mismo para usarse en el tratamiento tópico o profilaxis de sudoración excesiva, y composiciones que contienen estos ingredientes.
MX2016001465A 2013-07-30 2014-07-30 Composiciones topicas para el tratamiento de sudoracion excesiva y metodos para utilizar las mismas. MX2016001465A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361859947P 2013-07-30 2013-07-30
US201461952238P 2014-03-13 2014-03-13
US201462021878P 2014-07-08 2014-07-08
PCT/IB2014/063564 WO2015015446A1 (en) 2013-07-30 2014-07-30 Topical compositions for treatment of excessive sweating and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2016001465A true MX2016001465A (es) 2016-06-02

Family

ID=51626097

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001465A MX2016001465A (es) 2013-07-30 2014-07-30 Composiciones topicas para el tratamiento de sudoracion excesiva y metodos para utilizar las mismas.

Country Status (17)

Country Link
US (2) US20160166487A1 (es)
EP (1) EP3027184A1 (es)
JP (1) JP2016525569A (es)
KR (1) KR20160034920A (es)
CN (1) CN105555269A (es)
AU (1) AU2014297993A1 (es)
BR (1) BR112016001696A2 (es)
CA (1) CA2919979A1 (es)
CR (1) CR20160055A (es)
EA (1) EA201690302A1 (es)
HK (1) HK1225317A1 (es)
IL (1) IL243681A0 (es)
MX (1) MX2016001465A (es)
PE (1) PE20160198A1 (es)
PH (1) PH12016500096A1 (es)
SG (1) SG11201600045UA (es)
WO (1) WO2015015446A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015193631A1 (en) 2014-06-18 2015-12-23 Cipla Limited Pharmaceutical composition comprising a beta-2-agonist and anticholinergic agent
US20180228770A1 (en) * 2015-07-21 2018-08-16 Bodor Laboratories, Inc. Formulation for soft anticholinergic analogs
TWI719046B (zh) 2016-07-21 2021-02-21 美商波德實驗股份有限公司 軟性抗膽鹼類似物之製劑
EP3694491A1 (en) * 2017-10-10 2020-08-19 Capsugel Belgium NV Gelling multiparticulates
WO2021092090A1 (en) * 2019-11-05 2021-05-14 Dermira, Inc. Methods for palmar or plantar administration of pharmaceutical compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4824676A (en) * 1984-10-11 1989-04-25 Schering Corporation Physiological means of enhancing transdermal delivery of drugs
US4885282A (en) 1987-07-02 1989-12-05 Thornfeldt Carl R Treatment of hyperhidrosis, ichthyosis and wrinkling
US5512555A (en) 1994-07-21 1996-04-30 Merck & Co., Inc. Method of treating sweat-related conditions using finasteride, epristeride and a cholestan-3-one
US6433003B1 (en) 1999-04-23 2002-08-13 Arthur M. Bobrove Method for treating hyperhidrosis in mammals
US8980290B2 (en) * 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040192754A1 (en) 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
PT1729821E (pt) 2004-03-03 2013-10-23 Revance Therapeutics Inc Composições e métodos para aplicação tópica e administração transdérmica de toxinas botulínicas
PE20060259A1 (es) * 2004-04-27 2006-03-25 Glaxo Group Ltd Compuestos de quinuclidina como antagonistas del receptor de acetilcolina muscarinico
US8618160B2 (en) * 2007-10-18 2013-12-31 Rose U Topical glycopyrrolate formulations
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
CN104968656B (zh) * 2012-12-19 2017-08-11 诺华股份有限公司 自分泌运动因子抑制剂

Also Published As

Publication number Publication date
PH12016500096A1 (en) 2016-04-18
CN105555269A (zh) 2016-05-04
HK1225317A1 (zh) 2017-09-08
EA201690302A1 (ru) 2016-06-30
AU2014297993A1 (en) 2016-02-04
SG11201600045UA (en) 2016-02-26
JP2016525569A (ja) 2016-08-25
WO2015015446A1 (en) 2015-02-05
IL243681A0 (en) 2016-04-21
EP3027184A1 (en) 2016-06-08
US20150037269A1 (en) 2015-02-05
PE20160198A1 (es) 2016-04-21
BR112016001696A2 (pt) 2017-08-01
US20160166487A1 (en) 2016-06-16
CR20160055A (es) 2016-04-04
KR20160034920A (ko) 2016-03-30
CA2919979A1 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
PH12015502792A1 (en) Crystalline bromodomain inhibitors
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
IN2015DN01156A (es)
MX2015017215A (es) Compuestos de sulfonamida biciclicos como inhibidores de los canales de sodio.
PH12013502099A1 (en) 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one for use in the treatment of adenoid cystic carcinoma
MX2015017964A (es) Inhibidores de bromodominio.
EP4414376A3 (en) Novel depsipeptide and uses thereof
MX2015015518A (es) Metodos y composiciones para el tratamiento del cancer.
PH12014501991B1 (en) Phenicol antibacterials
PH12016500096A1 (en) Topical compositions for treatment of excessive sweating and methods of use thereof
EP4289820A3 (en) Compounds for use in treating alzheimer's disease in apoe4+/+ patients
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
BR112015022846A2 (pt) uso de um composto para tratar ou prevenir um angioedema mediado pelo receptor b2 da bradicinina e formulação compreendendo o mesmo
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
TN2018000214A1 (en) Alkyl dihydroquinoline sulfonamide compounds
MX373177B (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
PH12015501538A1 (en) Topical ocular analgesic agents
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
MX2017007978A (es) 3-(piperidin-4-il)-isoxazol-3(2h)-onas para tratamiento de trastornos dermatologicos.
MX2015014657A (es) Nuevos agentes antibacterianos de fenicol.
HK1210173A1 (en) Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators
CL2016000222A1 (es) Composiciones tópicas para el tratamiento de sudoración excesiva y métodos para utilizar las mismas
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.